Zacks: Analysts Anticipate Lipocine Inc. (LPCN) to Post -$0.31 Earnings Per Share
Equities analysts predict that Lipocine Inc. (NASDAQ:LPCN) will report earnings per share (EPS) of ($0.31) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Lipocine’s earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.26). Lipocine reported earnings per share of ($0.16) during the same quarter last year, which indicates a negative year over year growth rate of 93.8%. The company is scheduled to announce its next earnings report on Tuesday, November 14th.
According to Zacks, analysts expect that Lipocine will report full-year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.87) to ($0.85). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.24) per share, with EPS estimates ranging from ($0.53) to $0.25. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Lipocine.
Lipocine (NASDAQ:LPCN) last posted its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.01).
A number of equities research analysts recently issued reports on the company. Roth Capital set a $38.00 target price on Lipocine and gave the company a “buy” rating in a research report on Thursday, August 10th. ValuEngine lowered Lipocine from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Finally, Canaccord Genuity set a $11.00 target price on Lipocine and gave the company a “buy” rating in a research report on Monday, August 7th.
Lipocine (NASDAQ:LPCN) traded down 1.96% during trading on Friday, reaching $4.01. 122,955 shares of the company’s stock traded hands. The company has a 50-day moving average of $4.19 and a 200 day moving average of $4.05. The stock’s market capitalization is $82.53 million. Lipocine has a 12 month low of $3.03 and a 12 month high of $5.90.
Several large investors have recently bought and sold shares of LPCN. Vanguard Group Inc. increased its position in shares of Lipocine by 39.7% during the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after purchasing an additional 155,110 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Lipocine during the 2nd quarter worth approximately $300,000. Ameriprise Financial Inc. increased its position in shares of Lipocine by 99.4% during the 1st quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock worth $513,000 after purchasing an additional 65,600 shares during the last quarter. LMR Partners LLP acquired a new position in shares of Lipocine during the 2nd quarter worth approximately $173,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Lipocine by 27.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock worth $229,000 after purchasing an additional 12,518 shares during the last quarter. 26.39% of the stock is currently owned by hedge funds and other institutional investors.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.